Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$59.00T
24h Vol:
$9.82B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  ARWR

Arrowhead Pharmaceuticals Inc

ARWR
65 / 100
$31.59arrow_drop_up4.61%$1.39

Performance History

Stocklytics logo
Key Stats
Open$30.25
Prev. Close$30.20
EPS-2.77
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.91B
PE Ratio-
LOWHIGH
Day Range30.04
31.90
52 Week Range20.67
42.48
Ratios
P/B Ratio23.32
Revenue$240.73M
Operating M. %-3,845.26%
Earnings$0.00
Earnings Growth %-18.57%
EBITDA Margin %-118.53%
ROE %-106.24%
EPS-2.77

Score Breakdown

65vs 53. Market Avg.

All Score 65 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ARWRMARKET
Value4339
Quality5640
Ownership2919
Growth6346
Dividends-37
check_circle

Arrowhead Pharmaceuticals Inc's Price discount from all time high of 98.92% is great compared to market average of 40.99%. This indicates ARWR could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$769.53
24H (%)arrow_drop_down-0.01%
24H ($)-$0.10
MARKET CAP$731.18B
PRICE$527.23
24H (%)arrow_drop_up0.14%
24H ($)$0.73
MARKET CAP$487.65B
PRICE$161.84
24H (%)arrow_drop_up0.86%
24H ($)$1.39
MARKET CAP$389.83B
PRICE$129.45
24H (%)arrow_drop_up0.14%
24H ($)$0.19
MARKET CAP$328.02B

About Arrowhead Pharmaceuticals Inc (ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Christopher R. Anzalone Ph.D.
Headquarters
Pasadena
Employees
397
Exchange
NASDAQ
add Arrowhead Pharmaceuticals Inc to watchlist

Keep an eye on Arrowhead Pharmaceuticals Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Arrowhead Pharmaceuticals Inc's (ARWR) price per share?

The current price per share for Arrowhead Pharmaceuticals Inc (ARWR) is $31.6. The stock has seen a price change of $1.4 recently, indicating a 4.62% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Arrowhead Pharmaceuticals Inc (ARWR)?

For Arrowhead Pharmaceuticals Inc (ARWR), the 52-week high is $42.48, which is 34.45% from the current price. The 52-week low is $20.67, the current price is 52.85% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Arrowhead Pharmaceuticals Inc (ARWR) a growth stock?

Arrowhead Pharmaceuticals Inc (ARWR) has shown an average price growth of -25.15% over the past three years. It has received a score of 24 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Arrowhead Pharmaceuticals Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Arrowhead Pharmaceuticals Inc (ARWR) stock price performance year to date (YTD)?

As of the latest data, Arrowhead Pharmaceuticals Inc (ARWR) has a year-to-date price change of 1.95%. Over the past month, the stock has experienced a price change of -5.46%. Over the last three months, the change has been 10.05%. Over the past six months, the figure is 13.28%. Looking at a longer horizon, the five-year price change stands at 65.25%.

question_mark
Is Arrowhead Pharmaceuticals Inc (ARWR) a profitable company?

Arrowhead Pharmaceuticals Inc (ARWR) has a net income of -$209.28M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 100% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.85K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $240.74M, although specific revenue growth data is currently not available. The gross profit is $240.74M. Operating income is noted at -$205M. Furthermore, the EBITDA is -$285.35M.

question_mark
What is the market capitalization of Arrowhead Pharmaceuticals Inc (ARWR)?

Arrowhead Pharmaceuticals Inc (ARWR) has a market capitalization of $3.91B. The average daily trading volume is 1.35M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.